Tvardi Therapeutics, Inc. (NasdaqCM: TVRD)
Health Care · Pharmaceuticals · US
$1.03
0.00% today · -84.6% 1Y
Tvardi Therapeutics, Inc. (NasdaqCM: TVRD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $13.74M and employs 12 people.
Over the last twelve months the share price has lost 84.6%, trading between 0.93 and 43.65.
Tweenvest scores Tvardi Therapeutics, Inc. across four factors: quality 44/100, value 31/100. Its strongest factor is quality.
TVRD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.74M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.77
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $43.65
- 52-week low
- $0.93
- Avg volume (3M)
- —
- Shares outstanding
- 13.34M
- Employees
- 12
- Next earnings
- —
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
- ISIN
- US1407553072
- Founded
- 2017
- Listed since
- Jan 31, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pharma Equity Group A/SCPSE: PEG | $14.01M | Dkr0.08 | -2.06% |
| Parnax Lab LimitedBSE: 506128 | $13.89M | Rs117.00 | +1.74% |
| Biotika a.s.BSSE: 1BSL01AE | $13.81M | €— | — |
| Yi Po International Holding LimitedOTCPK: YBZN | $13.77M | $— | — |
| WooGene B&G Co., LtdKOSDAQ: A018620 | $13.72M | ₩2,660.00 | -0.19% |
| Citius Pharmaceuticals, Inc.NasdaqCM: CTXR | $13.71M | $0.48 | -3.62% |
| Lactose (India) LimitedBSE: 524202 | $13.52M | Rs103.95 | -1.38% |
| PT Phapros TbkIDX: PEHA | $13.52M | Rp288.00 | +2.86% |
Figures last refreshed Oct 11, 2026.